参麦-川芎嗪注射液辅助治疗慢性肺源性心脏病的疗效观察

Observation of the effects of Shenmai injection and ligustrazine injection in the adjuvant treatment of chronic pulmonary heart disease

目的探讨参麦、川芎嗪注射液辅助治疗慢性肺源性心脏病(肺心病)的疗效。方法选择肺心病患者40例(治疗组),在常规治疗的基础上加用参麦注射液及川芎嗪注射液治疗14天,并与40例常规治疗组(对照组)比较,观察治疗前后两组患者二氧化碳分压(Pa CO2)、血氧分压(Pa O2)和脑钠肽(BNP)的变化情况。结果治疗组治疗前Pa CO2、Pa O2、BNP水平分别为(73.99±5.63)mm Hg、(51.12±4.60)mm Hg和(3264.73±671.66)pg/ml,治疗后为(58.41±6.02)mm Hg、(63.71±3.53)mm Hg和(241.25±80.58)pg/ml;对照组治疗前为(73.90±4.75)mm Hg、(51.09±3.98)mm Hg和(3205.72±713.18)pg/ml,治疗后为(63.29±4.72)mm Hg、(57.95±3.68)mm Hg和(470.56±156.65)pg/ml。两组Pa CO2、BNP治疗前水平较高,治疗后水平下降(P<0.01),Pa O2治疗前水平较低,治疗后提高(P<0.01),提示两组治疗均有效,治疗前两组的Pa CO2、Pa O2和BNP水平比较差异无统计学意义(P>0.05),治疗后治疗组Pa CO2、BNP水平较对照组低,Pa O2水平较对照组高(P<0.01),提示参麦注射液和川芎嗪注射液辅助治疗肺心病疗效优于常规治疗组。结论参麦注射液联合川芎嗪注射液辅助治疗肺心病可有效改善慢性肺源性心脏病患者血清Pa CO2,Pa O2和BNP水平,对改善患者心肺功能,提高临床疗效有益。

Objective To investigate the effects of Shenmai injection and ligustrazine injection in the adjuvant treatment of chronic pulmonary heart disease. Methods 40 cases of pulmonary heart disease( treatment group) were treated with Shenmai injection and ligustrazine injection for 14 days on the basis of conventional treatment,and they were compared to 40cases( control group) who were treated with conventional treatment only. The changes of partial pressure of carbon dioxide( Pa CO2),partial pressure of oxygen( Pa O2) and brain natriuretic peptide( BNP) before and after treatment were observed in the two groups. Results Before treatment,levels of Pa CO2,Pa O2 and BNP in the treatment group were( 73. 99 ± 5. 63) mmHg,( 51. 12 ± 4. 60) mm Hg and( 3264. 73 ± 671. 66) pg / ml respectively,while those after treatment were( 58. 41 ± 6. 02)mm Hg,( 63. 71 ± 3. 53) mm Hg and( 241. 25 ± 80. 58) pg / ml respectively. Before treatment,levels of Pa CO2,Pa O2,BNP in the control group were( 73. 9 ± 4. 75) mm Hg,( 51. 09 ± 3. 98) mm Hg and( 3205. 72 ± 713. 18) pg / ml respectively,while those after treatment were( 63. 29 ± 4. 72) mm Hg,( 57. 95 ± 3. 68) mm Hg and( 470. 56 ± 156. 65) pg / ml respectively. Levels of Pa CO2,BNP in both groups were relatively high before treatment,but they decreased after treatment( P < 0. 01),Pa O2 level was relatively low,but it increased after treatment( P < 0. 01),which showed that both groups got positive effects in the treatment,and difference of Pa CO2,Pa O2 and BNP were not statistically significant before treatment in the two groups( P > 0.05). After treatment,the levels of Pa CO2 and BNP in the treatment group were lower than those in the control group,while Pa O2 level was higher than that of the control group( P < 0. 01),which showed that Shenmai injection and ligustrazine injection had better effect than conventional treatment in the adjuvant treatment of chronic pulmonary disease. Conclusion Shenmai injection combined with ligustrazine injection for pulmonary heart disease can effectively improve levels of serum Pa CO2,Pa O2 and BNP of patients with chronic pulmonary heart disease,which is beneficial to improve the heart and lung function of patients,and improve clinical efficacy.